The Asia-Pacific ECMO market is expected to grow from US$ 110.85 million in 2022 to US$ 139.19 million by 2028. It is estimated to record a CAGR of 3.9% from 2022 to 2028.
Increasing Survival Rates with ECMO to Offer Opportunities for Asia-Pacific ECMO Market During 2022–2028
The employment of ECMO for treating respiratory failure has been increasing in recent years, as treatments with ECMO show promising survival rates. Further, ECMO is recommended to treat patients suffering from acute respiratory distress syndrome (ADRS), primary graft dysfunction post lung transplant, and trauma to the lungs as it increases the survival rate of patients. Furthermore, ECMO increases the survival rate of patients affected by post-cardiac arrest regimen. A radical shift in adopting westernized lifestyles leads to various cardiac disorders. Thus, key players invest significantly in R&D, which results in improved treatment outcomes with ECMO with an increased survival rate. Therefore, the rising survival rate with ECMO use in various treatments is expected to provide lucrative opportunities for ECMO market in Asia-Pacific during the forecast period.
Asia-Pacific ECMO Market Overview
Asia-Pacific is the fastest-growing regional ECMO market. China, India, and Japan are major contributors to the Asia-Pacific ECMO market growth in the region. China dominated the market in 2022. According to an article by the National Center for Biotechnology Information (NCBI) titled "Cardiovascular Health and Diseases in China," Cardiovascular Disease (CVD) accounted for ~47% and 44% of all deaths in rural and urban areas, respectively, in 2019. Two out of every five deaths occur due to CVD, and it is predicted that over 330 million patients suffer from CVD in China. The patients suffering from stroke, heart failure, coronary heart disease, pulmonary heart disease, rheumatic heart disease, atrial fibrillation, lower extremity artery disease, congenital heart disease, and hypertension were found to be 13 million, 11 million, 9 million, 5 million, 4.87 million, 2.50 million, 2 million, 45.30 million, and 245.00 million, respectively. Moreover, according to Statista data, the population aged above 60 years is estimated to grow from 17.4% in 2020 to 30% by 2040. Thus, China is facing the pressures of an aging population and the constant rise in the prevalence of metabolic risk factors. As a result, the CVD burden will continue to increase, setting new requirements for CVD prevention, treatment, and the allocation of medical resources in China. Furthermore, the penetration of international market players in the country is boosting the growth of the ECMO market. In July 2021, Xenios AG, a Fresenius Medical Care company, received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. Hence, the rising prevalence of CVD, the increasing geriatric population, and advancements by key players are expected to propel the ECMO market in China during the forecast period.
Asia-Pacific ECMO Market Segmentation
The Asia-Pacific ECMO market is segmented based on modality, application, age group, and country.
Based on modality, the Asia-Pacific ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.
Based on application, the Asia-Pacific ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.
Based on age group, the Asia-Pacific ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.
Based on country, the Asia-Pacific ECMO market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Our regional analysis states that China dominated the market in 2022.
ABIOMED Inc, Braile Biomedica, Eurosets S.R.L., Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the Asia-Pacific ECMO market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 110.85 Million |
| Market Size by 2028 | US$ 139.19 Million |
| CAGR (2022 - 2028) | 3.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Modality
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
The Asia-Pacific ECMO Market is valued at US$ 110.85 Million in 2022, it is projected to reach US$ 139.19 Million by 2028.
As per our report Asia-Pacific ECMO Market, the market size is valued at US$ 110.85 Million in 2022, projecting it to reach US$ 139.19 Million by 2028. This translates to a CAGR of approximately 3.9% during the forecast period.
The Asia-Pacific ECMO Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific ECMO Market report:
The Asia-Pacific ECMO Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia-Pacific ECMO Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia-Pacific ECMO Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Asia-Pacific ECMO Market
